Jin Rong Jie·2025-08-20 19:35Core Viewpoint - Yifang Biopharma-U's stock price decreased by 1.13% to 40.39 CNY, with a trading volume of 474 million CNY, indicating market volatility and potential investor concerns regarding its financial dealings with partners [1] Company Overview - Yifang Biopharma-U operates in the biopharmaceutical industry, focusing on innovative drug development for oncology and metabolic diseases [1] - The company's product pipeline includes small molecule targeted therapies and biological macromolecule drugs [1] Financial Situation - Bidafarma disclosed in its 2025 semi-annual report that it still owes Yifang Biopharma 180 million CNY in milestone payments related to the co-development of the innovative drug Beifutine [1] - Yifang Biopharma has previously urged for payment and has made a 10% provision for bad debts, but Bidafarma has not provided a clear repayment schedule [1] Market Activity - On the day of the report, Yifang Biopharma-U experienced a net outflow of 27.61 million CNY in main funds, while there was a net inflow of 76.04 million CNY over the past five days [1]